Is ARIAD Pharmaceuticals, Inc. (ARIA) a Buy, Sell, or Hold?
NASDAQ : ARIA
ARIAD Pharmaceuticals, Inc. — News
$23.99 USD
$0.04 (0.17%)
- Volume
- 7.22M
- Average Volume
- 6.58M
- Market Capitalization
- $0
- P/E Ratio
- -19.83
- Dividend Yield
- 0.00%
- Price Target
- $33.00
- Year High
- $23.99
- Year Low
- $4.67
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.08
| Source | Headline |
|---|---|
|
Promis Reports No ARIA-E in PMN310 Alzheimer's Trial Interim Data
Promis Neurosciences NASDAQ: PMN reported blinded six-month interim data from its Phase 1b PRECISE-AD trial of PMN310, an investigational antibody designed to selectively target toxic amyloid-beta oligomers in patients with mild cognitive impairment due to Alzheimer's disease and early Alzheimer's disease. marketbeat.com - 2026-07-28 14:05:07 |
|
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer's Disease
[url="]Ionis Pharmaceuticals, Inc.[/url] (Nasdaq: IONS) today announced that its partner, Biogen, shared data from the Phase 2 CELIA study evaluating diranerse gurufocus.com - 2026-07-14 10:00:00 |
|
Braiin Launches Agentic AI Workforce ARIA to Capture the US$32.0 Billion Global Real Estate Software Market by 2033
ARIA brings agentic AI execution to property management, leasing, compliance, accounting support, and customer engagement globenewswire.com - 2026-07-13 08:30:00 |
|
CoreWeave ARIA Launches as an AI Research and Iteration Agent with autonomous research and collaborative intelligence
LIVINGSTON, N.J.--(BUSINESS WIRE)--CoreWeave, Inc. (Nasdaq: CRWV), The Essential Cloud for AI™, today announced the launch of CoreWeave ARIA (AI Research & Iteration Agent), an AI research agent built directly into Weights & Biases (W&B) by CoreWeave that reads experiment data, uncovers hidden insights, and drives continuous model and agent improvement. ARIA was built using W&B Weave, CoreWeave's agent development platform. W&B Weave's agent development capabilities also ent. businesswire.com - 2026-06-29 08:00:00 |
